Status:
COMPLETED
Brain Imaging and Treatment Studies of the Night Eating Syndrome
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
Forest Laboratories
Conditions:
Night Eating Syndrome
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome.
Detailed Description
This proposal explores the implications of our two recent major discoveries: the striking efficacy of the Selective Serotonin Reuptake Inhibitor (SSRI) sertraline in the control of the Night Eating Sy...
Eligibility Criteria
Inclusion
- men and women suffering from NES
- ages 18 to 70 years
- BMI greater than 18.5 kg/m2
Exclusion
- Children or adolescents \<18 years
- persons older than 70
- patients with diabetes mellitus
- thyroid disease and other endocrine and metabolic disorders
- use within the past month of any psychotropic medication, oral steroids, diuretics or hypnotics
- current anorexia nervosa or bulimia nervosa
- participation in an organized weight reduction program
- use of antiobesity medication
- an occupation that involves night shifts or other unusual time requirements -Major Depressive Disorder (judged severe)
- Bipolar Disorder
- suicidal risk
- current or past psychosis
- substance use or abuse disorder within the past 6 months
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT01401595
Start Date
December 1 2009
End Date
September 1 2011
Last Update
July 15 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Center for Weight and Eating Disorders
Philadelphia, Pennsylvania, United States, 19104